Ligand-activated transcription factor. Activated by high concentrations of 9-cis-retinoic acid and all-trans-retinoic acid, but not by dexamethasone, cortisol or progesterone (in vitro). Regulation of the apolipoprotein A-I gene transcription. Binds to DNA site A. Interacts with SQSTM1. Binds DNA as a dimer; homodimer or heterodimer with NR2F6. Interacts with NCOA1, NCOA2, NCOA3 and PPARGC1A. Interacts with ZFPM2. Ubiquitous. Belongs to the nuclear hormone receptor family. NR2 subfamily. 3 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Protein type: Motility/polarity/chemotaxis; Nuclear receptor; DNA binding protein
Cellular Component: nucleus
Molecular Function: protein binding; ligand-dependent nuclear receptor activity; retinoic acid binding; protein homodimerization activity; zinc ion binding; sequence-specific DNA binding; steroid hormone receptor activity; transcription corepressor activity; transcription factor activity
Biological Process: limb development; skeletal muscle development; intracellular receptor-mediated signaling pathway; positive regulation of transcription, DNA-dependent; neuron migration; negative regulation of cyclin-dependent protein kinase activity; negative regulation of transcription from RNA polymerase II promoter; signal transduction; response to estradiol stimulus; regulation of transcription from RNA polymerase II promoter; anterior/posterior pattern formation; negative regulation of endothelial cell proliferation; forebrain development; blood vessel morphogenesis; lipid metabolic process; negative regulation of transcription, DNA-dependent; radial pattern formation
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.